SUO 2018: Long-Term IO Alone for Muscle Invasive Bladder Cancer
Phoenix, Arizona (UroToday.com) As part of the bladder cancer session at the 2018 annual meeting of the Society of Urologic Oncology, Dr. Guru Sonpavde from the Dana-Farber Cancer Institute discussed the role of systemic monotherapy in the treatment of muscle invasive bladder cancer (MIBC), with a focus on immune-oncologic (IO) agents, such as PD-1 / PDL-1 inhibitors.
SUO 2018: What Do We Really Know about Financial Toxicity in Urologic Cancer Care?
Phoenix, Arizona (UroToday.com) During a panel discussion at Health Services Session on Financial Toxicity (FT) at SUO 2018, Dr. Seth Strope, a urologic oncologist at Baptist MD Anderson Cancer Center, Jacksonville, FL gave an excellent talk on FT among urologic cancer patients and survivors.
SUO 2018: The PROSPER Trial, A Post Hoc Analysis by Prior Definitive Surgery
Phoenix, Arizona (UroToday.com) The PROSPER trial, published in the New England Journal of Medicine in June 2018, demonstrated that in men with non-metastatic castrate-resistant prostate cancer with a rising PSA, treatment with enzalutamide led to a 71% lower risk of metastasis or death than placebo. Additionally, the median metastasis-free survival was 36.6 months in the enzalutamide group versus 14.7 months in the placebo group.
SUO 2018: PSMA-Guided Metastasis Directed Radiation
Phoenix, Arizona (UroToday.com) Dr. Tran, a radiation oncologist from Johns Hopkins University, provided the second talk of this section, focusing more on PSMA-guided metastasis-direction radiation, and specific, SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) – focal therapy with minimal adjacent tissue damage.
SUO 2018: Financial Toxicity and Cancer Treatment in America
Phoenix, Arizona (UroToday.com) Financial toxicity is a term popularized in 2015 to describe the problems that cancer patients have that are related to the costs of their cancer treatment. Recent studies show that cancer patients are more likely to have financial toxicity than people without cancer, and there are implications for quality of life, perceived quality of medical care, and financial security.
SUO 2018: The Platinum Study: Late Effects of Testicular Cancer and Its Treatment
Phoenix, Arizona (UroToday.com) In this talk, Dr. Travis, a pioneer in the field of testicular cancer survivorship, highlights the research to date in the field and the results of the Platinum Study, which focused on the late effects of testicular cancer and its treatments.
SUO 2018: Development of Serum MicroRNA as a Novel and Better Tumor Marker for Testicular Germ Cell Tumor than HCG and AFP
Phoenix, Arizona (UroToday.com) In this first talk by Dr. Kollmannsberger, the focus is on serum micro-RNA’s (miRNA) as a novel and potentially superior tumor marker for testicular germ cell tumors (GCTs) than HCG and AFP.